Author:
Souleiman Roni,Cornberg Markus
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Agarwal K, Brunetto M, Seto WK et al (2018) 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68:672–681. https://doi.org/10.1016/j.jhep.2017.11.039
2. Asselah T, Lampertico P, Wedemeyer H et al (2023) Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon alfa-2a in Patients with Chronic Hepatitis Delta: Primary Endpoint Results from a Phase 2b Open-Label, Randomized, Multicenter Study MYR204. In: AASLD:#5009
3. Asselah T, Rizzetto M (2023) Hepatitis D virus Infection. N Engl J Med 389:58–70. https://doi.org/10.1056/NEJMra2212151
4. Berg T, Lampertico P (2021) The times they are a‑changing—a refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 75:474–480. https://doi.org/10.1016/j.jhep.2021.04.040
5. van Bömmel F, Stein K, Heyne R et al (2023) A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J Hepatol 78:926–936. https://doi.org/10.1016/j.jhep.2022.12.018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献